Cell Based Immunotherapy


The invention hereby offered for licensing is in the field of Immunotherapy and more specifically in therapy of autoimmune diseases such as Type I diabetes, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosis and immune mediated allergies such as asthma as well as in transplantation-related disorders, such as graft acceptance and graft-versus-host-disease (GVHD).

While the role of FOXP3+ regulatory T cells (Tregs) in the maintenance of self-tolerance and immune homeostasis has been established and thus their use in adoptive immunotherapy has been contemplated, there is still no good way to purify and expand these cells in an efficient and reproducible manner ex vivo for use in human therapy. The subject invention provides a method that allows such purification for use in expansion cultures to generate sufficient numbers of cells and purity for cell-base immunotherapy. The method is based on the finding that Tregs selectively express Latency Associated Peptide (LAP) and CD121b (IL-1 Receptor Type 2) and on the ability to selectively separate these cells from other immune cells that are potentially hazardous, through the use of magnetic particles which specifically bind to either one of these two surface molecules and selectively separate those cells from the non-Tregs.

Potential Commercial Applications: Competitive Advantages:
  • Immunotherapy, primarily for autoimmune diseases such as Type I diabetes, hematologic disorders such as aplastic anemia, transplantation-related disorders, such as graft acceptance and graft-versus-host-disease (GVHD) and allergic diseases such as asthma.
  • Facilitating detailed studies and analysis of human Treg function in health and disease.
  • Assay to differentiate thymic-derived versus peripheral-derived FOXP3+ Tregs.
  • Potential assay to monitor disease status, progression and prognosis such as early detection or response to therapy of GVHD after transplantation, solid organ graft rejection post-transplantation or a flare-up of systemic lupus erythematosus.
 
  • The method of purification of FOXP3+ Tregs for human treatment may be superior in efficiency and practicality than currently existing techniques. After the magnetic separation, the final product contains more than 90% fully functional FOXP3+ Tregs. This novel protocol should facilitate the purification of Tregs for both cell-based therapy as well as for detailed studies of human Treg function in health and disease. It is important to note that most of the treatments for specific autoimmune diseases (i.e. hormone replacement therapy, enzyme replacement therapy, corticosteroids, NSAIDs, plasmapherisis, immunosuppressants and intravenous immunoglobulins) do not constitute cure for the specific diseases. Immunotherapy with Tregs has a potential to provide cure or prolonged remission for many of these diseases.


Development Stage:
The purification protocol has been proven simple and efficient in a laboratory setting.

Inventors:

Dat Tran (NIAID)  ➽ more inventions...

Ethan Shevach (NIAID)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 8,951,793 issued 2015-02-10
PCT Application No. PCT/US2009/054631
US Application No. 13/060,043

Publications:
Andersson J, et al. PMID 18710931
Shevach EM, et al. PMID 18395859
Tran DQ, et al. PMID 17644734

Collaboration Opportunity:

The NIAID/NIH Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the use of CD121b or LAP to produce a Treg product for cell-based immunotherapy. Please contact Richard Williams at 301-496-2644 for more information.


Licensing Contact:
Yogikala Prabhu,
Email: prabhuyo@niaid.nih.gov
Phone: 301-761-7789

OTT Reference No: E-312-2008-0
Updated: Sep 22, 2015